Hims & Hers Health, Inc. (HIMS)
| Market Cap | 9.37B |
| Revenue (ttm) | 1.78B |
| Net Income (ttm) | 164.40M |
| Shares Out | 223.67M |
| EPS (ttm) | 0.68 |
| PE Ratio | 61.48 |
| Forward PE | 52.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,477,761 |
| Open | 42.25 |
| Previous Close | 40.82 |
| Day's Range | 39.80 - 43.09 |
| 52-Week Range | 11.45 - 72.98 |
| Beta | 1.85 |
| Analysts | Hold |
| Price Target | 36.92 (-11.84%) |
| Earnings Date | May 5, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price forecast is $36.92, which is a decrease of -11.84% from the latest price.
News
Hims & Hers Health, Inc. (HIMS) Q1 2025 Earnings Call Transcript
Hims & Hers Health, Inc. (NYSE:HIMS) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Bill Newby - Head of Investor Relations Andrew Dudum - Co-Founder and Chief Executive...
Hims & Hers gives weak outlook but says more collaborations are coming
Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft guidance. For its second quarter, Hims & Hers said it expected to report reven...
Hims & Hers Health Revenue Jumps, But Outlook Disappoints
Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook missed Wall Street's expectations.
Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the first quarter...
HIMS Earnings Ahead: Wegovy Offers Upside, Analysts Advise Caution
"There's a sense of caution" heading into Hims & Hers (HIMS) earnings, says Caroline Woods. The telehealth company is up over 65% so far in 2025 but has fallen more than 40% off its February highs.
Hims & Hers: The Next Amazon? Novo Nordisk Might Be Prime Delivery
Hims & Hers Health Inc. HIMS is suddenly looking like the hottest prescription in town – up 220% in the past year and turning heads with a bold new partnership that might just reshape digital healthca...
Hims & Hers brings former Amazon executive into C-suite
Hims & Hers Health announced Nader Kabbani will join the telehealth company as its new chief operations officer. Kabbani spent nearly 20 years at Amazon, where he oversaw the launch of Amazon Pharmacy...
Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A season...
Hims & Hers: Revolutionizing Healthcare
The company's vertically integrated platform enhances scalability and efficiency, controlling the entire patient experience from consultation to medication delivery. Partnerships, especially with Novo...
Hims & Hers stock price soars after partnership with Novo Nordisk to offer weight-loss drug Wegovy
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordi...
Hims & Hers Health: GLP-1 Deals De-Risk The Story
Hims & Hers Health partners with Novo Nordisk to offer Wegovy, de-risking investment but not significantly altering the business focus on personalized healthcare solutions. The health and wellness pla...
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.
Hims & Hers partners with Novo Nordisk to sell Wegovy
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/mon...
White House Slams AMZN, HIMS & NVO Wegovy Partnership, SOFI Rallies
Amazon (AMZN) shares faced selling pressure after the White House called the company's decision to display tariff costs on products a "hostile and political act." Diane King Hall notes it's just the l...
Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
Hims & Hers Health (HIMS) stock surges 34% on partnership with Novo Nordisk to sell Wegovy
Shares of Hims & Hers Health soared more than 34% in premarket trading on Tuesday after Novo Nordisk announced a partnership with the telehealth company to expand access to its popular weight loss dru...
Hims & Hers' stock rockets after teaming up with its rival Wegovy maker
Health and wellness company Hims & Hers, which sells alternatives to weight-loss drugs like Wegovy, is now collaborating with the maker of Wegovy.
Hims & Hers Stock Soars 45%. Why a Deal With Novo Nordisk for Weight-Loss Drugs Matters.
The companies announced a long-term collaboration to make obesity treatments more affordable, they said on Tuesday.
Novo Nordisk opens weight loss drug Wegovy to Hims & Hers, Ro and Life MD telehealth
Novo Nordisk said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and Life MD. The Danish drugmaker is racing to capture more patients now that many comp...
Hims & Hers partners with Novo Nordisk to sell Wegovy on its platform
Danish drugmaker Novo Nordisk has partnered with Hims & Hers Health's to sell its popular weight loss drug through a bundled offering on the telehealth company's platform, the two companies said on Tu...
Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care
SAN FRANCISCO--(BUSINESS WIRE)--Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more accessible, mo...
Hims & Hers: Selling Options On This High-Growth Gem Could Yield 20% Or More (Rating Upgrade)
Hims & Hers boasts excellent underlying performance, but the stock's current valuation remains uncomfortably high. Despite a 40% drop in stock price, shares are not yet a value, and selling put option...
Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy
Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business, presenting a buying opportunity for long-term investors. The company is ramping up liraglutide manufactur...
Hims & Hers: Top Pick For The Next Decade
Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Despite the high short interest and bear arguments, HIMS' data-driven personalization...